Table 5. Correlation between clinicopathological factors and expression of MDR1/P-gp and MRP-1 protein in primary tumours only.
| Characteristics | No. of cases | MDR P-gp (%) | P | No. of cases | MRP-1 (%) | P |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <59 | 19/42 | 45.2 | 0.402 | 22/42 | 52.4 | 0.463 |
| ⩾59 | 27/50 | 54.0 | 30/50 | 60.0 | ||
| Gender | ||||||
| Male | 14/30 | 46.7 | 0.656 | 21/30 | 70.0 | 0.070 |
| Female | 32/62 | 51.6 | 31/62 | 50.0 | ||
| Lymph node spread | ||||||
| Negative | 40/85 | 47.1 | 0.049* | 46/85 | 54.1 | 0.105 |
| Positive | 6/7 | 85.7 | 6/7 | 85.7 | ||
| Clark's level | ||||||
| II and III | 20/41 | 48.8 | 0.251 | 19/41 | 46.3 | 0.051 |
| IV and V | 17/27 | 63.0 | 19/27 | 70.3 | ||
| Clark's level | ||||||
| II, III, IV | 32/62 | 51.6 | 0.136 | 32/62 | 51.6 | 0.023* |
| V | 5/6 | 83.3 | 6/6 | 100.0 | ||
| Breslow thickness | ||||||
| and lt;1 mm | 14/29 | 48.3 | 0.056 | 12/29 | 41.4 | 0.139 |
| 1–4 mm | 11/27 | 40.7 | 15/27 | 55.6 | ||
| >4 mm | 15/20 | 75.0 | 14/20 | 70.0 | ||
| Relapse | ||||||
| Relapse within 5 years | 11/23 | 47.8 | 0.587 | 10/23 | 43.5 | 0.137 |
Abbreviations: MDR1/P-gp=multi-drug resistance; MRP=multidrug resistance-associated protein. P values from χ2 analyses; *indicates significant parameter; Clark's score – information was available for 68 of 92 cases; Breslow's thickness – information was available for 76 of 92 cases; relapse information available for 36 cases.